140 related articles for article (PubMed ID: 38753055)
1. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.
Li JB; Lai MY; Lin ZC; Guan WL; Sun YT; Yang J; Wang WX; Yang ZR; Qiu MZ
Cancer Immunol Immunother; 2024 May; 73(7):132. PubMed ID: 38753055
[TBL] [Abstract][Full Text] [Related]
2. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
[TBL] [Abstract][Full Text] [Related]
9. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
10. Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.
Li Y; Liang X; Li H; Chen X
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212119
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
[TBL] [Abstract][Full Text] [Related]
14. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
15. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J; Jiang H; Pan Y; Gu K; Cang S; Han L; Shu Y; Li J; Zhao J; Pan H; Luo S; Qin Y; Guo Q; Bai Y; Ling Y; Yang J; Yan Z; Yang L; Tang Y; He Y; Zhang L; Liang X; Niu Z; Zhang J; Mao Y; Guo Y; Peng B; Li Z; Liu Y; Wang Y; Zhou H;
JAMA; 2023 Dec; 330(21):2064-2074. PubMed ID: 38051328
[TBL] [Abstract][Full Text] [Related]
16. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
Yoon HH; Jin Z; Kour O; Kankeu Fonkoua LA; Shitara K; Gibson MK; Prokop LJ; Moehler M; Kang YK; Shi Q; Ajani JA
JAMA Oncol; 2022 Oct; 8(10):1456-1465. PubMed ID: 36006624
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
Wu HX; Pan YQ; He Y; Wang ZX; Guan WL; Chen YX; Yao YC; Shao NY; Xu RH; Wang F
J Clin Oncol; 2023 Mar; 41(9):1735-1746. PubMed ID: 36473145
[TBL] [Abstract][Full Text] [Related]
18. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
19. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]